Enkephalins as possible adrenomedullary hormones: storage, secretion, and regulation of synthesis. 1980

O H Viveros, and E J Diliberto, and E Hazum, and K J Chang

UI MeSH Term Description Entries
D004723 Endorphins One of the three major groups of endogenous opioid peptides. They are large peptides derived from the PRO-OPIOMELANOCORTIN precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; OPIOID PEPTIDES is used for the broader group. Endorphin
D004745 Enkephalins One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. Enkephalin
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D000313 Adrenal Medulla The inner portion of the adrenal gland. Derived from ECTODERM, adrenal medulla consists mainly of CHROMAFFIN CELLS that produces and stores a number of NEUROTRANSMITTERS, mainly adrenaline (EPINEPHRINE) and NOREPINEPHRINE. The activity of the adrenal medulla is regulated by the SYMPATHETIC NERVOUS SYSTEM. Adrenal Medullas,Medulla, Adrenal,Medullas, Adrenal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
January 1982, Advances in biochemical psychopharmacology,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
January 1979, Pharmacology,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
January 1972, The Scientific basis of medicine annual reviews,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
January 1984, Acta physiologica Scandinavica,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
March 1968, Canadian journal of physiology and pharmacology,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
June 1992, Endocrinology,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
June 2008, Physiology & behavior,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
January 1998, Advances in pharmacology (San Diego, Calif.),
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
August 1987, International journal of pancreatology : official journal of the International Association of Pancreatology,
O H Viveros, and E J Diliberto, and E Hazum, and K J Chang
December 1950, British medical journal,
Copied contents to your clipboard!